MSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.

Pulmonary hypertension (PH), a serious lung and heart condition, elevates blood pressure in lung arteries, causing shortness ...

The ability to characterize the pulmonary circulation more fully paved the way for many advances. In the 1950s, Dr David ...

Winrevair lowered death or transplant risk in adults with PAH functional class 3-4 at high risk of dying; all in study may ...

我与大家分享的主题是肺循环血流动力学在肺动脉高压评估中的临床应用。在日常临床实践中，超声检查是最为常用的肺动脉高压诊断工具之一，它能够提供实用的血流动力学参数，包括压力测量、三尖瓣收缩期位移、心腔大小等，有的研究还发现通过心脏超声可以估算出心排血量、 ...

Advancements and Projections in the Global Pulmonary Arterial Hypertension Market: Insights, Trends, Opportunities, and ...

The advice to " go with your gut " is ubiquitous but not always on point. For instance, your gut may tell you not to apply ...

New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.

When most people hear the word hypertension, they think of high blood pressure. While not as common as high blood pressure, ...

The company plans to use the proceeds to advance its pipeline of Activin and GDF inhibitors, HS135 for pulmonary hypertension ...

Recent health news highlights major developments in pharmaceuticals, including Merck's promising Winrevair for pulmonary ...

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim ...